Fennec Pharmaceuticals announces Q1 2024 financial results release on May 14th, discussing PEDMARK and PEDMARQSI approvals.
Fennec Pharmaceuticals, a specialty pharma firm, will release Q1 2024 financial results on May 14th. PEDMARK received FDA approval in Sep 2022, while PEDMARQSI received EC Marketing Authorization in June 2023 and UK approval in Oct 2023, both focusing on reducing platinum-induced ototoxicity in pediatric patients. A call & webcast at 8:30 AM ET on the 14th will discuss financial performance.
May 07, 2024
4 Articles